State-of-the-art strategies for targeting the DNA damage response in cancer
Genomic instability is a key hallmark of cancer that arises owing to defects in the DNA
damage response (DDR) and/or increased replication stress. These alterations promote the …
damage response (DDR) and/or increased replication stress. These alterations promote the …
Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches
M Orth, P Metzger, S Gerum, J Mayerle, G Schneider… - Radiation …, 2019 - Springer
Pancreatic ductal adenocarcinoma (PDAC) is a highly devastating disease with poor
prognosis and rising incidence. Late detection and a particularly aggressive biology are the …
prognosis and rising incidence. Late detection and a particularly aggressive biology are the …
Exploring and comparing adverse events between PARP inhibitors
CJ LaFargue, GZ Dal Molin, AK Sood… - The lancet …, 2019 - thelancet.com
Ovarian cancer remains one of the most challenging malignancies to treat. Targeted
therapies such as poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as one of …
therapies such as poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as one of …
Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer
PA Konstantinopoulos, R Ceccaldi, GI Shapiro… - Cancer discovery, 2015 - AACR
Approximately 50% of epithelial ovarian cancers (EOC) exhibit defective DNA repair via
homologous recombination (HR) due to genetic and epigenetic alterations of HR pathway …
homologous recombination (HR) due to genetic and epigenetic alterations of HR pathway …
Biomarker-guided development of DNA repair inhibitors
JM Cleary, AJ Aguirre, GI Shapiro, AD D'Andrea - Molecular cell, 2020 - cell.com
Anti-cancer drugs targeting the DNA damage response (DDR) exploit genetic or functional
defects in this pathway through synthetic lethal mechanisms. For example, defects in …
defects in this pathway through synthetic lethal mechanisms. For example, defects in …
Targeting topoisomerase I in the era of precision medicine
Irinotecan and topotecan have been widely used as anticancer drugs for the past 20 years.
Because of their selectivity as topoisomerase I (TOP1) inhibitors that trap TOP1 cleavage …
Because of their selectivity as topoisomerase I (TOP1) inhibitors that trap TOP1 cleavage …
Visualizing engrafted human cancer and therapy responses in immunodeficient zebrafish
Xenograft cell transplantation into immunodeficient mice has become the gold standard for
assessing pre-clinical efficacy of cancer drugs, yet direct visualization of single-cell …
assessing pre-clinical efficacy of cancer drugs, yet direct visualization of single-cell …
An update on PARP inhibitors—moving to the adjuvant setting
A Sonnenblick, E De Azambuja, HA Azim Jr… - Nature reviews Clinical …, 2015 - nature.com
Inhibition of poly (ADP-ribose) polymerase (PARP) enzymes is a potential synthetic lethal
therapeutic strategy in cancers harbouring specific DNA-repair defects, including those …
therapeutic strategy in cancers harbouring specific DNA-repair defects, including those …
PARP inhibitors in the management of breast cancer: current data and future prospects
L Livraghi, JE Garber - BMC medicine, 2015 - Springer
Abstract Poly (ADP-ribose) polymerases (PARP) are enzymes involved in DNA-damage
repair. Inhibition of PARPs is a promising strategy for targeting cancers with defective DNA …
repair. Inhibition of PARPs is a promising strategy for targeting cancers with defective DNA …
BRCA1/2 testing: therapeutic implications for breast cancer management
NM Tung, JE Garber - British journal of cancer, 2018 - nature.com
Testing for germline BRCA 1/2 mutations has an established predictive role in breast cancer
risk assessment. More recently, studies have also identified BRCA 1/2 status as clinically …
risk assessment. More recently, studies have also identified BRCA 1/2 status as clinically …